July 2016 — Located in Cambridge, MA, Intellia Therapeutics is the most recent Biotech company to recognize R&D Logic's unique life sciences specialization. Intellia's combination of deep scientific expertise and clinical development experience, along with their leading intellectual property portfolio, puts them in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products.

April 2016 — Located in Cambridge, MA, Spero Therapeutics is the latest life science company to select R&D Logic's Life Sciences specialty solution to manage their R&D intensive company. Spero's mission is to develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease.

April 2016 — Located in Newton, MA, Karyopharm Therapeutics is the latest life science company in this explosive Biotech hub to select the R&D Logic solution to manage their R&D intensive company. Karyopharm's mission is to discover and develop first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

March 2016 — Located in San Bruno, CA, Balance Therapeutics has selected R&D Logic's Life Sciences specialty solution to manage their R&D intensive company. Balance is focused on developing therapeutics to address neurological disabilities resulting from excess inhibition of the brain.

January 2016 — Located in San Francisco, CA, Nurix has selected R&D Logic's Life Sciences specialty solution to manage their R&D intensive company. Nurix is passionate in its mission of pioneering the development of small molecules that modulate the ubiquitin proteasome system (UPS) for improvement of human health.

November 2015 — Located in Watertown, MA, Forma Therapeutics has selected the R&D Logic FP&A solution to manage their R&D intensive company. Forma is passionate about discovering and developing medicines that will make a difference in cancer and other genetically-driven diseases.

October 2015 — Viking, located in San Diego, California has selected R&D Logic's software for planning, tracking, analysis and reporting. Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.

May 2015 — Just, located in Seattle, Washington has selected R&D Logic's software for planning, tracking, analysis and reporting. Just is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. Just believes that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.

January 2015 — Retrophin, located in New York, Cambridge and San Diego has selected R&D Logic's software for collecting and reporting R&D project effort and FTEs. Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.

September 2014 — Juno, located in Seattle, Washington has selected R&D Logic's software for planning, tracking, anlysis and reporting. Juno is a clinical-stage company that brings together three of the world's leading cancer centers - Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute - in unique partnership to advance a broad pipeline of breakthrough immunotherapies.

July 2014 — Acceleron, located in Cambridge, Massachusetts has selected R&D Logic's software for collecting and reporting project effort and FTEs. Acceleron aims to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies.

June 2014 — Mersana, located in Cambridge, Massachusetts has selected R&D Logic's software for collecting and reporting project effort and time off. Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Mersana technology harnesses the power and synergy of nanotechnology, biologics and small molecules has built a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research.

February 2014 — Ipsen Bioscience, a subsidiary of Ipsen, located in Milford, Massachusetts has selected R&D Logic software and services to manage their planning, tracking and reporting processes. Formerly Biomeasure, this research center in the Ipsen Group and is focused on discovering drugs in neuro-endocrinology.

February 2014 — XOMA Corporation, located in Berkeley, California has selected R&D Logic platform to support global planning, tracking and reporting of the R&D porfolio and the overall corporation. XOMA has built a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research.

January 2014 — Sutro Biopharma, located in South San Francisco, California has selected R&D Logic software and services to develop long term, mid-term and operational budgetes and to track, analyze and manage variances to actual results. In addition, Sutro employees and contractors will track their time effort to project using the RDLogic platform. Sutro Biopharma is developing a new generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies.